VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study

VBI Vaccines announced the completion of enrollment with the last patient receiving the first dose in the ongoing PROTECT Phase 3 study of Sci-B-Vac®, the company’s third-generation hepatitis B vaccine. More than 1,600 adults have now been enrolled in the PROTECT study at 27 sites across the U.S., Europe, and Canada. 

Click here to read the full release

Previous
Previous

OBIO Pre-CAAP Company Adrenalease Launches KickStarter Campaign

Next
Next

OBIO CAAP Company CellAegis Announces First Patients Enrolled in U.S. SHIELD Pivotal Clinical Trial